Bromocriptine use is associated with decreased smoking rates.

Bromocriptine use is associated with decreased smoking rates.

Dopaminergic transmission in the central nervous system is thought to underlie addictive behaviours, including smoking. One effective smoking cessation drug, bupropion, enhances dopaminergic transmission; conversely, antipsychotic drugs, which are dopamine antagonists, are associated with increased...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Murphy, M, Hey, K, Johnstone, E, Munafo, M, Walton, R, Willis, B, Harrison, P
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2002

Παρόμοια τεκμήρια

Association of the mu-opioid receptor gene with smoking cessation.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2007)

The genetic basis for smoking behavior: a systematic review and meta-analysis.
ανά: Munafò, M, κ.ά.
Έκδοση: (2004)

Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.
ανά: Johnstone, E, κ.ά.
Έκδοση: (2007)

Association of COMT Val108/158Met genotype with smoking cessation.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2008)

Central Hyperthermia Treated with Bromocriptine
ανά: P. Natteru, κ.ά.
Έκδοση: (2017-01-01)

Does cigarette smoking increase time to conception?
ανά: Munafo, M, κ.ά.
Έκδοση: (2002)

Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt.
ανά: Johnstone, E, κ.ά.
Έκδοση: (2004)

Is giving up smoking on the nicotine patch related to genotype?
ανά: Yudkin, P, κ.ά.
Έκδοση: (2001)

Smoking cessation, weight gain, and DRD4 -521 genotype
ανά: Munafò, MR, κ.ά.
Έκδοση: (2006)

Cabergoline or bromocriptine for prolactinoma?
ανά: Nicolás Triantafilo, κ.ά.
Έκδοση: (2016-09-01)

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial
ανά: Munafo, M, κ.ά.
Έκδοση: (2009)

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2009)

Smoking status moderates the association of the dopamine D4 receptor (DRD4) gene VNTR polymorphism with selective processing of smoking-related cues.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2008)

Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.
ανά: David, S, κ.ά.
Έκδοση: (2008)

Lack of association of OPRM1 genotype and smoking cessation.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2013)

Genes and cigarette smoking.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2008)

No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation.
ανά: David, S, κ.ά.
Έκδοση: (2002)

Bromocriptine in the Management of Central Hyperthermia
ανά: Krishnaprasad Narayanankutty, κ.ά.
Έκδοση: (2024-08-01)

Repurposing of Bromocriptine for Cancer Therapy
ανά: Ean-Jeong Seo, κ.ά.
Έκδοση: (2018-10-01)

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial.
ανά: Yudkin, P, κ.ά.
Έκδοση: (2004)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
ανά: Rebecca Simon, κ.ά.
Έκδοση: (2018-10-01)

Bromocriptine and insulin sensitivity in lean and obese subjects
ανά: L Bahler, κ.ά.
Έκδοση: (2016-11-01)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
ανά: Grossman, A, κ.ά.
Έκδοση: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
ανά: Grossman, A, κ.ά.
Έκδοση: (1986)

Bromocriptine for type 2 diabetes mellitus
ανά: Ooi, Cheow Peng, κ.ά.
Έκδοση: (2013)

Bromocriptine in type 2 diabetes mellitus
ανά: C Shivaprasad, κ.ά.
Έκδοση: (2011-01-01)

Association between nicotinic acetylcholine receptor single nucleotide polymorphisms and smoking cessation.
ανά: Spruell, T, κ.ά.
Έκδοση: (2012)

Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials.
ανά: David, S, κ.ά.
Έκδοση: (2011)

Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch.
ανά: Yudkin, P, κ.ά.
Έκδοση: (2003)

CHRNA3 rs1051730 genotype and short-term smoking cessation.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2011)

A peripartum cardiomyopathy case treated with bromocriptine
ανά: Dilek Yeşilbursa, κ.ά.
Έκδοση: (2021-03-01)

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea
ανά: Ismail, I.S., κ.ά.
Έκδοση: (1994)

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
ανά: O A Gerasimenko, κ.ά.
Έκδοση: (2011-12-01)

Maternal smoking during late pregnancy and offspring smoking behaviour.
ανά: Munafò, MR, κ.ά.
Έκδοση: (2006)

Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement.
ανά: Uhl, G, κ.ά.
Έκδοση: (2010)

Effects of dopamine D2 receptor gene polymorphisms on smoking cessation: Abstinence and withdrawal symptoms
ανά: Munafo, MR, κ.ά.
Έκδοση: (2007)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
ανά: Yiqun Tang, κ.ά.
Έκδοση: (2023-03-01)

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
ανά: Grossman, A, κ.ά.
Έκδοση: (1987)

Weekly versus basic smoking cessation support in primary care: a randomised controlled trial.
ανά: Aveyard, P, κ.ά.
Έκδοση: (2007)

The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial.
ανά: David, S, κ.ά.
Έκδοση: (2007)